Suppr超能文献

肌肉减少症对女性癌症影响的过程:系统评价和荟萃分析。

The influence process of sarcopenia on female cancer: A systematic review and meta-analysis.

机构信息

Imaging Center of the First Affiliated Hospital of Xinjiang Medical University, Xinjiang, China.

出版信息

J Obstet Gynaecol Res. 2021 Dec;47(12):4403-4413. doi: 10.1111/jog.15012. Epub 2021 Sep 8.

Abstract

BACKGROUND

Sarcopenia is one of the early pathological manifestations of cancer cachexia. This change in quality and function has a general and special impact on the prognosis of many types of tumors. However, there are few studies to evaluate the overall impact of sarcopenia on the prognosis of gynecological tumors in sufficient follow-up period.

METHODS

This study systematically searched PubMed, EMBASE, web of science, and MEDLINE databases for related studies and related references since April 15, 2021. The 1-year, 5-year overall survival (OS), progression-free survival (PFS), hazard ratio (HR), and 95% confidence interval (CI) were analyzed by Stata 14.0.(CRD 42021236036).

RESULTS

A total of 23 observational studies involving 3495 female patients were included in the analysis, with an average prevalence of 46.9% (38.5%-55.3%). Meta-analysis showed that the 1-year OS (RR: 1.60, 95% CI = [1.04, 2.46]) of patients with sarcopenia was significantly lower than that of patients without sarcopenia, and then this effect gradually decreased. The results showed that sarcopenia was an independent predictor of OS (HR: 1.78, 95% CI = [1.38, 2.30]) and PFS (HR: 1.32, 95% CI = [1.02, 1.70]) in gynecological cancer patients. Subgroup analysis showed that sarcopenia was significant in Asian population (HR: 1.93, 95% CI = [1.18, 3.17]) and cervical cancer patients (HR: 5.07, 95% CI = [2.82, 9.56]).

CONCLUSION

The survival and recurrence outcome of patients with sarcopenia independently related to surgery, and its impact is very obvious in the short term. In addition, Asian participants with sarcopenia face a greater risk of death than Western participants.

摘要

背景

肌少症是癌症恶病质的早期病理表现之一。这种质量和功能的改变对多种肿瘤的预后有普遍和特殊的影响。然而,很少有研究在足够的随访期内评估肌少症对妇科肿瘤总体预后的影响。

方法

本研究系统地检索了 PubMed、EMBASE、Web of Science 和 MEDLINE 数据库,以获取自 2021 年 4 月 15 日以来的相关研究和参考文献。使用 Stata 14.0 分析 1 年、5 年总生存率(OS)、无进展生存率(PFS)、风险比(HR)和 95%置信区间(CI)。(CRD42021236036)。

结果

共纳入 23 项观察性研究,涉及 3495 名女性患者,平均患病率为 46.9%(38.5%-55.3%)。荟萃分析显示,肌少症患者 1 年 OS(RR:1.60,95%CI=[1.04,2.46])明显低于无肌少症患者,且该效应逐渐减弱。结果表明,肌少症是妇科癌症患者 OS(HR:1.78,95%CI=[1.38,2.30])和 PFS(HR:1.32,95%CI=[1.02,1.70])的独立预测因素。亚组分析显示,肌少症在亚洲人群(HR:1.93,95%CI=[1.18,3.17])和宫颈癌患者(HR:5.07,95%CI=[2.82,9.56])中具有显著意义。

结论

肌少症与手术相关的患者生存和复发结局独立相关,其影响在短期内非常明显。此外,肌少症的亚洲参与者比西方参与者面临更大的死亡风险。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验